• Funding Decisions


    New Funding Model

    Second Wave or Early Applicants
    Country Board-approved funding (Currency USD) Date approved Documents
    Renewals
    funding
    Indicative
    funding
    Incentive
    funding
    Total incremental
    amount
    Regional Artemisinin
    Resistance Initiative
    (RAI)

    RCM
    Malaria
    n/a 100,000,000 n/a 100,000,000 20 December 2013
    Eurasian Harm
    Reduction Network
    (EHRN)

    Regional Organization
    HIV/AIDS
    n/a 6,249,882 n/a 6,249,882 28 February 2014
    The Regional Malaria
    Elimination Initiative in
    Mesoamerica and Hispaniola
    (EMMIE)

    RCM
    Malaria
    n/a 10,000,000 n/a 10,000,000 28 February 2014
    Philippines
    CCM
    Tuberculosis
    n/a 39,379,997 n/a 39,379,997 28 February 2014
    Early Applicants
    Country Board-approved funding (Currency USD) Date approved Documents
    Renewals
    funding
    Indicative
    funding
    Incentive
    funding
    Total incremental
    amount
    El Salvador
    CCM
    HIV/AIDS
    3,882,694 20,150,000 2,924,388 26,957,082 14 June 2013
    Myanmar
    CCM
    HIV/AIDS
    91,700,000 39,500,000 30,000,000 161,200,000 14 June 2013
    Myanmar
    CCM
    Tuberculosis
    42,418,736 26,300,000 14,000,000 82,718,736 14 June 2013
    Myanmar
    CCM
    Malaria
    34,314,525 26,040,000 12,000,000 72,354,525 14 June 2013
    Zimbabwe
    CCM
    HIV/AIDS
    - 278,878,962 - 278,878,962 14 June 2013

    Concept notes were submitted and reviewed prior to the grant-making process. The upper-ceilings for funding and parameters for the grant-making process were set based on the TRP’s recommendations, following an assessment of the concept note, and further review by the Secretariat. It is important to note that the Board’s funding decision was based on a disbursement-ready grant, which has been developed into the final grant agreement. As a result of the grant-making process, the final grant agreement may differ significantly from the concept note.

    For further details on the review and approval process, as well as grant-making documentation, please refer to: New Funding Model page.

    Transitional Funding Mechanism - August 2012

    Total*

    • 45 disease proposals approved in 37 different countries, totaling a maximum upper-ceiling of US$ 419.8 million (categories 1-3)
    • 11 proposals from 10 countries must be revised and resubmitted for a second TRP review before a funding recommendation can be made (category 4), for a potential total two-year upper ceiling of US$ 91.2 million

    By Disease (Cat. 1-3)

    • HIV US$ 111.7 million in 16 countries
    • Tuberculosis US$ 103.8 million in 18 countries
    • Malaria US$ 204.2 million in 11 countries

    Documentation

    Please note: So as not to distort the country statistics, 1 multi-country proposal has been counted as 1 country count, unless otherwise stated.

    * US dollar/Euro exchange rate, 1 July 2012. Please note that amounts per region and disease do not take into account any anticipated adjustments to be achieved during TRP clarifications and grant negotiations.

    Round Based Channel

    Round 10 - December 2010

    Total

    • 79 disease proposals (including HSS requests) approved in 64 different countries, totaling a maximum upper-ceiling of US$ 1.73 billion

    By Global Fund Region(initial two years)

    • East Asia & the Pacific - US$ 211 million for 14 disease proposals (including HSS requests) in 11 countries
    • Eastern Europe & Central Asia - US$ 208 million for 10 disease proposals in 8 countries
    • Latin America & the Caribbean - US$ 36 million for 8 disease proposals (including HSS requests) in 8 countries
    • North Africa & the Middle East - US$ 261 million for 14 disease proposals (including HSS requests) in 9 countries
    • South West Asia - US$ 82 million for 5 disease proposals (including HSS requests) in 5 countries
    • Sub-Saharan Africa: East Africa - US$ 330 million for 9 disease proposals (including HSS requests) in 5 countries
    • Sub-Saharan Africa: Southern Africa - US$ 336 million for 7 disease proposals in 6 countries
    • Sub-Saharan Africa: West & Central Africa - 269 million for 12 disease proposals (including HSS requests) in 9 countries

    By Disease (initial two years, excluding HSS requests)

    • HIV US$ 732 million in 32 countries
    • Tuberculosis US$ 300 million in 26 countries
    • Malaria US$ 574 million in 18 countries

    Documentation

    Please note: So as not to distort the country statistics, 1 multi-country proposal has been counted as 1 country count, unless otherwise stated.

    * US dollar/Euro exchange rate, 1 December 2010. Please note that amounts per region and disease do not take into account any anticipated adjustments to be achieved during TRP clarifications and grant negotiations.

    Round 9 and NSA - November 2009*

    Total

    • 90 Round 9 disease proposals (including HSS requests) and National Strategy Applications (NSA) in 69 different countries approved, in principle, by the Board on 10 November 2009. It is noted that the TRP funding recommendations are collectively intended to be subject to a 10% adjustment downwards for efficiency, resulting in an adjusted maximum Phase 1 upper-ceiling funding of US$ 2.38 billion

    By Region

    • East Asia & the Pacific - US$ 473.6** million for 12 disease proposals (including HSS requests) in 7 countries
    • Eastern Europe & Central Asia - US$ 107.6** million for 12 disease proposals in 10 countries
    • Latin America & the Caribbean - US$ 185.5** million for 17 disease proposals (including HSS requests) in 14 countries
    • North Africa & the Middle East - US$ 87.3** million for 5 disease proposals (including HSS requests) in 5 countries
    • South West Asia - US$ 233.8** million for 8 disease proposals (including HSS requests) in 6 countries
    • Sub-Saharan Africa: East Africa - US$ 709.4** million for 11 disease proposals (including HSS requests) in 9 countries
    • Sub-Saharan Africa: Southern Africa - US$ 258.9** million for 7 disease proposals in 6 countries
    • Sub-Saharan Africa: West & Central Africa - US$ 592.1** million for 18 disease proposals (including HSS requests) in 12 countries

    By Disease

    • HIV US$ 1,198** million in 36 countries
    • Tuberculosis US$ 666.6** million in 35 countries
    • Malaria US$ 783.1** million in 19 countries

    Documentation

    * USD exchange rate November 2009.

    ** Please note that amounts per region and disease do not include a 10% downward adjustment for efficiency anticipated to be achieved during TRP clarifications and grant negotiations.

    Round 8 - November 2008

    Total

    • 110 programs in 68 countries approved in principle 8 November 2008 . It is noted that the Round 8 proposals are collectively intended to be subject to a 10% adjustment downwards for efficiency, resulting in an adjusted maximum Phase 1 upper ceiling funding of US$2.753 billion

    By Region

    • East Asia & the Pacific - US$ 387.4* million for 17 programs in 9 countries
    • Eastern Europe & Central Asia - US$ 141.9* million for 16 programs in 9 countries
    • Latin America & the Caribbean - US$ 161.9* million for 11 programs in 10 countries
    • North Africa & the Middle East - US$ 147.4* million for 10 programs in 7 countries
    • South Asia - US $ 98.3* million for 8 programs in 5 countries
    • Sub-Saharan Africa: East Africa - US$ 796.1* million for 15 programs in 10 countries
    • Sub-Saharan Africa: Southern Africa - US$ 414.0* million for 13 programs in 5 countries
    • Sub-Saharan Africa: West & Central Africa - US$ 912.3* million for 20 programs in 13 countries

    By Disease

    • HIVUS$ 1,164* million for programs in 37 countries
    • Malaria US$ 1,568* million programs in 28 countries
    • Tuberculosis US$ 327* million for programs in 29 countries

    Documentation

    * Please note that amounts per region and disease do not include a 10% downward adjustment for efficiency anticipated to be achieved during TRP clarifications and grant negotiations.

    Round 7 - November 2007

    Total

    • Total approved US$ 1,119 million 73 programs in 66 countries/economies*

    By Region

    • East Asia & the Pacific - US$ 92 million for 11 programs in 19 countries/ economies*
    • Eastern Europe & Central Asia - US$ 38 million for 5 programs in 5 countries/ economies
    • Latin America & the Caribbean - US$ 54 million for 10 programs in 11 countries/ economies*
    • North Africa & the Middle East - US$ 164 million for 10 programs in 7 countries/ economies
    • South Asia - US $97 million for 9 programs in 6 countries/economies
    • Sub-Saharan Africa: East Africa - US$ 385 million for 9 programs in 8 countries/ economies
    • Sub-Saharan Africa: Southern Africa - US$ 154 million for 8 programs in 6 countries/economies
    • Sub-Saharan Africa: West & Central Africa - US$ 134 million for 11 programs in 8 countries/economies

    By Disease

    • HIV US$ 537 million for 26 programs in 39 countries/economies*
    • Malaria US$ 471 million for 28 programs in 27 countries/economies
    • Tuberculosis US$ 111 million for 19 programs in 30 countries/economies*

    Documentation

    *Including countries/economies targeted in the multi – country proposal

    Round 6 - November 2006

    Total

    • Total approved US$ 846 million in 63 countries

    By Region

    • East Asia & the Pacific - US$ 107 million in 8 countries
    • Eastern Europe & Central Asia - US$ 119 million in 12 country
    • Latin America & the Caribbean - US$ 47 million in 4 countries
    • North Africa & the Middle East - US$ 70 million in 9 countries
    • South Asia - US$ 129 million in 5 countries
    • Sub-Saharan Africa: East Africa - US$ 94 million in 7 countries
    • Sub-Saharan Africa: Southern Africa - US$ 117 million in 4 countries
    • Sub-Saharan Africa: West & Central Africa - US$ 159 million in 14 countries

    By Disease

    • HIV US$ 453 million in 34 countries
    • Malaria US$ 202 million in 19 countries
    • Tuberculosis US$ 190 million in 34 countries

    Documentation

    Round 5 - September 2005

    Total

    • Total approved US$ 770 million in 60 countries

    By Region

    • East Asia & the Pacific - US$ 128 million in 17 countries
    • Eastern Europe & Central Asia - US$ 27 million in 8 country
    • Latin America & the Caribbean - US$ 54 million in 4 countries
    • North Africa & the Middle East - US$ 63 million in 4 countries
    • South Asia - US$ 24 million in 2 countries
    • Sub-Saharan Africa: East Africa - US$ 135 million in 5 countries
    • Sub-Saharan Africa: Southern Africa - US$ 124 million in 8 countries
    • Sub-Saharan Africa: West & Central Africa - US$ 210 million in 12 countries

    By Disease

    • HIV US$ 315 million in 25 countries
    • HSS US$ 38 million in 3 countries
    • Malaria US$ 202 million in 26 countries
    • Tuberculosis US$ 213 million in 23 countries

    Documentation

    Round 4 - June 2004

    Total

    • Total approved US$ 1,039 million in 52 countries

    By Region

    • Africa - US$ 663 million for 34 programs in 23 countries
    • Asia, Middle East & North Africa - US$237 million for 23 programs in 16 countries
    • Latin America, Caribbean & Eastern Europe - US$ 139 million for 15 programs in 13 countries

    By Disease

    • HIV US$ 469 m in 27 countries
    • Malaria US$ 417 m in 23 countries
    • Tuberculosis US$ 153 m in 21 countries

    Documentation

    Round 3 - November 2003

    Total

    • US$ 623m for 71 programs in 61 countries

    By Region

    • Africa - US$ 365m for 34 programs in 23 countries
    • Asia, Middle East & North Africa - US$ 127m for 15 programs in 13 countries
    • Latin America, Caribbean & Eastern Europe - US$ 130m for 22 programs in 25 countries

    By Disease

    • HIV US$ 362m for 31 programs in 52 countries
    • HIV/TB US$ 27m for 2 programs in 2 countries
    • Malaria US$ 166m for 20 programs in 20 countries
    • Tuberculosis US$ 68m for 18 programs in 18 countries

    Documentation

    Round 2 - January 2003

    Total

    • US$ 866 million for 98 programs in 73 countries

    By Region

    • Africa - US$ 550m for 49 programs in 30 countries
    • Asia, Middle East & North Africa - US$ 145m for 27 programs in 27 countries
    • Latin America, Caribbean & Eastern Europe - US$ 171m for 22 programs in 16 countries

    By Disease

    • HIV US$ 487m for 43 programs in 52 countries
    • HIV/TB US$ 8m for 1 program in 1 country
    • Integrated US$ 3m for 1 program in 1 country
    • Malaria US$ 242m for 28 programs in 37 countries
    • Tuberculosis US$ 126m for 25 programs in 35 countries

    Documentation

    Round 1 - April 2002

    Total

    • US$ 565 million for 55 programs in 36 countries

    By Region

    • Africa - US$ 308m for 27 programs in 16 countries
    • Asia, Middle East & North Africa - US$ 151m for 18 programs in 11 countries
    • Latin America, Caribbean & Eastern Europe - US$ 106m for 10 programs in 9 countries

    By Disease

    • HIV US$ 326m for 26 programs in 22 countries
    • HIV/TB US$ 55m for 4 programs in 3 countries
    • Integrated US$ 20m for 1 program in 1 country
    • Malaria US$ 68m for 12 programs in 12 countries
    • Tuberculosis US$ 96m for 12 programs in 12 countries

    Documentation

    Rolling Continuation Channel (RCC)

    Summary of RCC Final Resubmission Wave Funding Decisions August 2010

    Total

    • US$ 6,952,123

    By Country

    • Sao Tome e Principe (Malaria) - US$ 6,952,123

    Documentation

    Summary of RCC Wave 8 Funding Decisions March 2010

    Total

    • US$ 305,938,252 in five countries

    By Country

    • Guyana - US$ 3,217,761
    • Guatemala - US$ 100,966,712
    • Lao PDR - US$ 11,642,882
    • South Africa - US$ 143,086,769
    • Uzbekistan - US$ 47,024,128

    By Disease

    • HIV and AIDS - US$ 290,719,768
    • Malaria - US$ US$ 15,218,484

    Documentation

    Summary of RCC Wave 7 Funding Decisions November 2009

    Total

    • US$ 1,125,636,284 in seven countries

    By Country

    • China - US$ 404,818,780
    • India - US$ 390,464,765
    • Mongolia - US$ 8,540,561
    • Namibia - US$ 230,943,957
    • Tanzania - US$ 56,466,4747
    • The Gambia - US$ 26,450,793
    • Georgia - EUR 5,374,845

    By Disease

    • HIV and AIDS* - US$ 658,734,300
    • Tuberculosis - US$ 423,087,271
    • Malaria - US$ 43,814,713

    Documentation

    *Including HSS cross-cutting interventions

    Summary of RCC Wave 6 Funding Decisions May 2009

    Total

    • US $552,040,988 in nine countries

    By Country

    • Bangladesh - US$ 81,312,404
    • Belarus - US$ 14,340,567
    • Guyana - US$ 47,035,818
    • India - US$ 302,056,162
    • Nepal - US$ 31,950,775
    • Rwanda - US$ 13,700,861
    • Paraguay - US$ 5,481,613
    • Russia - EUR 9,288,623
    • Georgia - EUR 33,338,933

    By Disease

    • HIV and AIDS - US$ 488,669,764
    • Tuberculosis - US$ 31,420,449
    • Malaria - US$ 31,950,775

    Documentation

    Summary of RCC Wave 5 Funding Decisions February 2009

    Total

    • US$ 229,193,583 in six countries

    By Country

    • Armenia - US$ 11,906,034
    • Benin - US$ 60,422,029
    • China - US$ 205,031,814
    • Dominican Republic - US$ 6,405,790
    • Madagascar - US$ 33,798,784
    • Tajikistan - US$ 4,382,023

    By Disease

    • HIV and AIDS - US$ 216,937,848
    • Tuberculosis - US$ 10,787,813
    • Malaria - US$ 94,220,813

    Documentation

    Summary of RCC Wave 4 Funding Decisions October 2008

    Total

    • US $229,193,583 in five countries

    By Country

    • Dominican Republic - US $45,770,388
    • El Salvador - US$ 14,398,031
    • Ghana - US$ 89,764,243
    • India - US$ 72,095,018
    • Nicaragua - US$ 7,165,903

    By Disease

    • HIV and AIDS - US $60,168,419
    • Tuberculosis - US$ 79,260,921
    • Malaria - US$ 89,764,243

    Documentation

    Summary of RCC Wave 3 Funding Decisions July 2008

    Total

    • US$ 513,349,804 in eight countries

    By Country

    • Bulgaria - US $28,021,697
    • Cambodia - US$ 19,540,113
    • China - US$ 42,840,814
    • Cuba - US$ 9,772,998
    • Ethiopia - US$ 342,574,327
    • Haiti - US$ 46,136,317
    • Honduras - US$ 3,453,657
    • MCWP - US$ 21,009,881

    By Disease

    • HIV and AIDS - US $426,505,339
    • Tuberculosis - US$ 42,840,814
    • Malaria - US$ 44,003,651

    Documentation

    Summary of RCC Wave 2 Funding Decisions April 2008

    Total

    • US $364,489,068 in five countries

    By Country

    • Malawi - US$ 173,329,414
    • Mongolia - US$ 3,481,740
    • RMCC - US$ 14,384,472
    • Thailand - US$ 56,157,021
    • Philippines - US$ 117,136,422

    By Disease

    • HIV and AIDS - US$ 232,968,175
    • Tuberculosis - US$ 78,037,991
    • Malaria - US$ 53,482,903

    Documentation

    Summary of RCC Wave 1 Funding Decisions November 2007

    Total

    • US$ 129,713,262 in five countries

    By Country

    • Burundi - US$19,694,151
    • Honduras - US$ 25,121,194
    • Mongolia - US$ 3,553,729
    • Rwanda - US$ 21,346,817
    • Tanzania - US$ 59,997,371

    By Disease

    • HIV and AIDS - US$ 47,187,023
    • Tuberculosis - US$ 8,454,963
    • Malaria - US$ 151,443,365

    Documentation

    Affordable Medicines Facility - malaria (AMFm)

    AMFm Phase 1 - November 2009

    Total

    • 10 applications to AMFm Phase 1 were approved on 11 November 2009. The total budget for supporting interventions across these applications was US$126.7 million. Of this, US$ 17.6 was requested in new funding from the Global Fund. The majority of funding for supporting interventions will be provided through reprogramming savings gained in participating countries' existing Global Fund malaria grants through the lower cost of artemisinin-based combination therapies (ACTs) under AMFm.

    By Region

    • East Asia & the Pacific - 1 application approved with a total budget for supporting interventions of US$11 million (US$9.6 requested in new funding from the Global Fund)
    • North Africa & Middle East - 1 application approved with a total budget for supporting interventions of US$2.1 million (US$1.7 million requested in new funding from the Global Fund)
    • Sub-Saharan Africa: East Africa & Indian Ocean - 6 applications approved with a total budget for supporting interventions of US$47.8 million (US$6.3 million requested in new funding from the Global Fund)
    • Sub-Saharan Africa: West & Central Africa - 2 applications approved with a total budget for supporting interventions of US$65.8 million (no new funding requested from the Global Fund)

    Documentation